U.S. stock-index futures rose on Wednesday as investors cheered better-than-expected earnings from Morgan Stanley.
Monsanto said a sweetened $125-per-share offer from chemicals group Bayer is "financially inadequate and insufficient to ensure deal certainty."
Boutique banks have increased their market share of M&A over big Wall Street firms year over year.
U.S. sovereign bond yields pared gains after gunfire was heard and jets were seen flying in the Turkish capital of Ankara.
U.S. stock indexes futures traded higher Friday after better-than-expected retail sales.
Even though Bayer sweetened the pot in its attempt to win Monsanto, analysts suggest the seed company's board is likely to reject the offer.
The good news first: it's likely getting better. Of course, that comes as big banks try to rebound from the bad news: it's been the worst start to a year, on a number of metrics, since the global financial crisis.
Boutique banks have taken more of traditional banks’ cherished revenue driver this year than in 2015.
Politicians and regulators out to prevent monopolies kill inversion deals put a big crimp in a key Wall Street business.
European stocks rose in late trade Thursday as Bank of England Governor Mark Carney gave a dovish speech over the fallout from the U.K.'s referendum result.
During a third-quarter earnings call, Monsanto management said talks with German suitor Bayer and other parties are ongoing.
The pace of mergers and acquisitions in agribusiness shows no signs of letting up.
2016 on track for the strongest year of foreign acquisitions in the U.S.
Dennis Gartman, the founder and publisher of the Gartman Letter, told CNBC on Wednesday that Monday and Tuesday's market gains could continue for the next couple of weeks.
Dennis Gartman, founder, editor & publisher of The Gartman Letter, comments on Monsanto's decision to reject the Bayer acquisition proposal.
Europe closed sharply up on Tuesday, as sentiment was lifted by positive U.S. trade, and strong gains from banks, insurers and retailers.
Kirsty Wilson, senior analyst at Mergermarket, looks at the potential bidders for U.S. agrichemicals giant Monsanto, including potential interest from China.
Neil Dwane, global strategist at Allianz Global Investors, says many Bayer investors will view the deal negatively as they won't own Monsanto.
John Rountree, managing partner at Novasecta, talks about whether or not the Bayer-Monsanto merger would create more or less innovation and value.
Scott Moeller, director of the M&A Research Centre at Cass Business School, and John Rountree, from Novasecta, discuss the Bayer-Monsanto deal.